Rilonacept for Cardiac Sarcoidosis
Trial Summary
What is the purpose of this trial?
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it does mention that you cannot start new immunosuppressive drugs or increase the dose of existing ones close to the trial's start. It's best to discuss your specific medications with the trial team.
How does the drug Rilonacept differ from other treatments for cardiac sarcoidosis?
Rilonacept is unique because it targets interleukin-1 (IL-1), a protein involved in inflammation, which is different from other treatments like corticosteroids or TNFα antagonists that suppress the immune system more broadly. This specific targeting may offer a novel approach for managing inflammation in cardiac sarcoidosis.12345
Research Team
Andrew Rosenbaum
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for adults aged 18-80 with cardiac sarcoidosis, evidenced by active FDG uptake in the heart. Participants must understand and agree to study requirements, have completed vaccinations, and use effective contraception if applicable. Exclusions include pregnancy, weight over 380 pounds, other severe health conditions or treatments that could affect results.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive rilonacept added to standard therapy or standard therapy alone for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Rilonacept
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Johns Hopkins University
Collaborator